(Reuters) – The U.S. Food and Drug Administration on Wednesday removed a boxed warning about increased risk of leg and foot amputations with Johnson & Johnson’s diabetes drug Invokana.
Invokana was approved in 2017 to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Reviews of new clinical data also showed the drug had additional heart and kidney related benefits, the agency said.
